Injexate

Methotrexate, the active ingredient in Injexate, is an antimetabolite (folate antagonist) presented as a subcutaneous injection for systemic use. It is employed to manage autoimmune disorders such as rheumatoid arthritis and psoriasis, as well as certain malignancies, by suppressing abnormal cell proliferation. It is approved for use in the European Union.

GNH USA supplies Injexate as a licensed, GDP‑compliant international pharmaceutical supplier, delivering the product to hospitals, oncology centres, pharmacies, and clinics worldwide while ensuring quality, regulatory compliance, and reliable cold‑chain logistics for injectable medicines.

Methotrexate is used to treat autoimmune and oncologic conditions by interfering with folate‑dependent cellular processes.

- Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: diminishes skin plaque formation and severity. - Acute lymphoblastic leukemia: inhibits rapid proliferation of malignant lymphoblasts. - Osteosarcoma: impedes tumor growth by blocking DNA synthesis in bone cancer cells.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting. - Fatigue or general weakness. - Oral mucosal ulceration (mouth sores). - Elevated liver enzymes. - Transient low blood cell counts. - Mild hair thinning.

Serious or Rare Side Effects: - Severe hepatotoxicity or liver fibrosis. - Pulmonary fibrosis or interstitial pneumonitis. - Life‑threatening bone marrow suppression. - Acute kidney injury. - Severe skin reactions such as Stevens‑Johnson syndrome. - Opportunistic infections due to immunosuppression.

When using Injexate, several safety measures should be observed.

- Pregnancy: avoid use unless clearly indicated; discuss risks with a specialist. - Liver function: monitor hepatic enzymes regularly. - Renal function: assess kidney status before initiation and during therapy. - Hematology: perform routine complete blood counts to detect cytopenias. - Drug interactions: review concomitant medications for potential additive toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several medicines that may increase toxicity or reduce efficacy.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs). - Trimethoprim‑sulfamethoxazole. - Live vaccines (e.g., measles, varicella).

Moderate Interactions (Monitor Closely): - Azathioprine. - Proton pump inhibitors. - Phenytoin.